Chimeric antigen receptor tumor infiltrating lymphocytes

Abstract

Disclosed are compositions and methods for targeted treatment of infections and cancers expressing cancers. In particular, tumor infiltrating lymphocytes (TILs) are genetically engineered to express chimeric antigen receptor (CAR) polypeptides to produce CAR-TILs that can be used with adoptive cell transfer to target, penetrate, and kill solid tumor masses. Therefore, also disclosed are methods of providing an immunotherapy in a subject with an infection or cancer that involves adoptive transfer of the disclosed CAR-TILs.

Description

[0001] Cross References to Related Applications

[0002] This application claims priority to U.S. Provisional Application No. 62 / 683,792, filed June 12, 2018, and Application Serial No. 62 / 857,054, filed June 4, 2019, the entire contents of which are incorporated herein by reference. Background technique

[0003] Surgery, radiation therapy and chemotherapy have been standard accepted methods of treating cancer including leukemia, solid tumors and metastasis. Immunotherapy (sometimes called biological therapy (biotherapy) or biological response modifier therapy), which directly or indirectly uses the body's immune system to shrink or eradicate cancer, has been studied over the years as an adjunct to conventional cancer therapy. It is believed that the human immune system is an untapped resource for cancer therapy and that once components of the immune system are properly utilized, effective treatments can be developed.

[0004] Chimeric antigen receptors (CARs) are engineered ...

Images